ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
This Quarter Return
+2.32%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$7.07B
AUM Growth
+$7.07B
(+3.1%)
Cap. Flow
+$370M
Cap. Flow
% of AUM
5.23%
Top 10 Holdings %
Top 10 Hldgs %
69.18%
Holding
43
New
7
Increased
10
Reduced
7
Closed
3
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$103M |
| 2 |
Alkermes
ALKS
|
$70.5M |
| 3 |
Vera Therapeutics
VERA
|
$55M |
| 4 |
Arrowhead Research
ARWR
|
$41.8M |
| 5 |
uniQure
QURE
|
$38.4M |
Top Sells
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$37.8M |
| 2 |
United Therapeutics
UTHR
|
$34.8M |
| 3 |
Dyne Therapeutics
DYN
|
$23.3M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$21.3M |
| 5 |
Spyre Therapeutics
SYRE
|
$17.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
uniQure
QURE
$946M
| $38.4M | 0.54% |
+2,175,000
| New | +$38.4M |
|
27
Ultragenyx Pharmaceutical
RARE
$3.07B
| $34.9M | 0.49% |
830,000
| – | – |
|
28
Taysha Gene Therapies
TSHA
$786M
| $34.6M | 0.49% |
19,999,999
+1,349,999
| +7% | +$2.34M |
|
29
89bio
ETNB
$1.36B
| $32.1M | 0.45% |
+4,100,000
| New | +$32.1M |
|
30
Monte Rosa Therapeutics
GLUE
$309M
| $30.2M | 0.43% |
4,345,000
-1,445,236
| -25% | -$10M |
|
|
31
Syndax Pharmaceuticals
SNDX
$1.38B
| $30.1M | 0.43% |
2,275,000
-1,613,437
| -41% | -$21.3M |
|
32
Iovance Biotherapeutics
IOVA
$800M
| $25.9M | 0.37% |
3,500,000
-740,000
| -17% | -$5.48M |
|
|
SEPN
33
Septerna, Inc. Common Stock
SEPN
$625M
| $25.4M | 0.36% |
+1,110,000
| New | +$25.4M |
|
|
AUTL
34
Autolus Therapeutics
AUTL
$397M
| $23.3M | 0.33% |
9,910,642
-2,435,036
| -20% | -$5.72M |
|
35
CG Oncology
CGON
$2.12B
| $20.1M | 0.28% |
700,000
| – | – |
|
36
Kura Oncology
KURA
$720M
| $19.6M | 0.28% |
2,250,000
-1,291,505
| -36% | -$11.2M |
|
37
Rocket Pharmaceuticals
RCKT
$356M
| $15.1M | 0.21% |
+1,200,000
| New | +$15.1M |
|
38
Olema Pharmaceuticals
OLMA
$428M
| $9.63M | 0.14% |
+1,651,982
| New | +$9.63M |
|
|
WHWK
39
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$85.3M
| $8.99M | 0.13% |
2,849,402
| – | – |
|
|
40
Dyne Therapeutics
DYN
$1.9B
| – | – |
-650,000
| Closed | -$23.3M |
|
41
Insmed
INSM
$30.2B
| – | – |
0
| – | – |
|
42
Neurogene
NGNE
$276M
| – | – |
-22,029
| Closed | -$924K |
|
|
43
Spyre Therapeutics
SYRE
$1.01B
| – | – |
-598,600
| Closed | -$17.6M |
|